Negative symptoms in schizophrenia: considerations for clinical trials - Working group on negative symptoms in schizophrenia

Psychopharmacology

Volumn 115, Issue 1-2, 1994, Pages 221-228

  Moller H J ^a   van Praag, H M ^b   Aufdembrinke, B ^c   Bailey, P ^d   Barnes, T R E ^e   Beck, J ^f   Bentsen, H ^g   Eich, F X ^f   Farrow, L ^h   Fleischhacker, W W ⁱ   Gerlach, J ^j   Grafford, K ^k   Hentschel, B ^l   Hertkorn, A ^d   Heylen, S ^m   Lecrubier, Y ⁿ   Leonard, J P ^d   McKenna, P ^o   Maier, W ^p   Pedersen, V ^q   Rappard, A ^r   Rein, W ^l   Ryan, J ^h   Sloth Nielsen, M ^s   Stieglitz, R D ^t   Wegener, G ^u   Wilson, J ^v   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Academic Psychiatric Centre ^*  (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^f Synthélabo Recherche ^*  (Germany)

^g Gaustad Hospital   (Norway)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^j Sct Hans Hospital   (Denmark)

^k Astra Arcus AB   (Sweden)

^l SANOFI   (France)

^m JANSSEN RESEARCH FOUNDATION   (Belgium)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o FULBOURN HOSPITAL   (United Kingdom)

^p UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^q H LUNDBECK A S   (Denmark)

^r JANSSEN CILAG GMBH   (Germany)

^s NOVO NORDISK A S   (Denmark)

^t UNIVERSITY OF FREIBURG   (Germany)

^u MERCK KGAA   (Germany)

^v GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

clinical trials; negative symptoms; neuroleptics; psychiatric status rating scales; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; BIPERIDEN; CERULETIDE; CLONAZEPAM; CLOZAPINE; FENFLURAMINE; FLUOXETINE; FLUPENTIXOL; FLUSPIRILENE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEUROLEPTIC AGENT; PENFLURIDOL; PIMOZIDE; PSYCHOTROPIC AGENT; REMOXIPRIDE; RISPERIDONE; SULPIRIDE; TIOTIXENE; TRANYLCYPROMINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZOTEPINE;

ARTICLE; CLINICAL TRIAL; DEFENSE MECHANISM; DEPRESSION; DRUG THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METHODOLOGY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STANDARDIZATION; THERAPY;

CLINICAL TRIALS; HUMAN; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0028234804     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02244775     Document Type: Article

References (92)

1. A rating scale for emotional blunting
2. The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia
3. Negative symptoms in schizophrenia. Definition and reliability
4. Report on the 3rd Consensus Conference on the methodology of clinical trials with anti-psychotic drugs
5. Quality of life of schizophrenic patients on medications and implications for new drug trials
6. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale
7. Methods for reliable longitudinal observationof behavior
8. The concept of the negative symptoms of schizophrenia
9. Molecular pathology of schizophrenia: more than one disease process?
10. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy
11. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia
12. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome
13. The Nurses Observation Scale for Inpatient Evaluation
14. Negative symptoms and the early course of schizophrenia
15. A negative symptom rating scale
16. Do negative symptoms respond to pharmacological treatment?
17. Methods for measuring adjustment and social behavior in the community: rationale, description, discriminative validity and scale development
18. Significance of the positive-negative distinction in schizophrenia
19. Predicting outcome of schizophrenia. Significance of symptom profiles and outcome dimensions
20. Pyramidical model in schizophrenia
21. Positive and negative symptoms in schizophrenia as a function of chronicity
22. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
23. The schedule for the deficit syndrome: an instrument for research in schizophrenia
24. A standardized psychiatric assessment scale for rating chronic psychotic patients
25. The symptoms of chronic schizophrenia: a reexamination of the positive-negative dichotomy
26. Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up
27. Negative symptoms in schizophrenia: a target for new drug development
28. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties
29. Neue Aspekte in der Diagnostik, Pathogenese und Therapie schizophrener Minussymptomatik
30. Clinical global impressions
31. Clinical and biochemical effects of nicergoline in chronic schizophrenic patients
32. Fenfluramine treatment of negative symptoms in older schizophrenic inpatients
33. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766)
34. Etude de l'efficacité de faibles doses de neuroleptiques atypiques (benzamides) dans les états déficitaires
35. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration
36. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
37. Differential response to amphetamine in schizophrenia
38. Risperidone versus Haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study
39. Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study
40. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms
41. A double-blind comparative trial of remoxipride and haloperidol in the treatment of schizophrenia
42. Zotepine, a neuroleptic drug with a bipolar therapeutic profile
43. The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia
44. Pimozide treatment of the negative schizophrenic syndrome: an open trial
45. Low-dose zotepine in the maintenance treatment of schizophrenia
46. Zotepine in the treatment of negative symptoms in chronic schizophrenia
47. Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics
48. Pilot clinical investigation of risperidone in the treatment of psychotic patients
49. The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms: Results of an open study
50. The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs
51. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients
52. Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study
53. Adjunctive clonazepam in the treatment of chronic schizophrenia
54. The effects of ceruletide in schizophrenia
55. Effect of L-dopa in schizophrenia
56. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia
57. Clozpaine for the treatment-resistant schizophrenic
58. L-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study
59. A double-blind comparison of pimozide and chlopromazine in the maintenance care of chronic schizophrenic outpatients
60. A controlled study of penfluridol in the treatment of chronic schizophrenia
61. Pimozide and the social behavior of schizophrenics
62. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia
63. A prospective study of clozapine in treatment-resistant schizophrenic patients
64. Effects of mianserin on negative symptoms in schizophrenia
65. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics
66. The effect of sulpiride on negative symptoms of schizophrenia
67. Response to negative symptoms of schizophrenia to neuroleptic treatment
68. High-dose propranolol in schizophrenia
69. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on, double-blind, placebo-controlled study
70. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap
71. Adjunctive imipramine maintenance in postpsychotic depression/negative symptoms
72. Sulpiride in negative schizophrenia: a placebo-controlled double blind assessment
73. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients
74. Treatment of negative schizophrenic symptoms with trihexyphenidyl
75. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients
76. Muscarinic cholinergic hyperactivity in schizophrenia
77. Effects of verapamil administration on negative symptoms of chronic schizophrenia
78. Dextro-amphetamine diminishes negative symptoms in schizophrenia
79. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
80. Le dogmatil dans le traitement des symptômes négatifs chez des patients schizophrènes
81. Pimozide vs chlorpromazine in chronic schizophrenia: a 52-week double-blind study of maintenance therapy
82. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia
83. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients
84. Effect of maprotiline combined with conventional neuroleptics against negative symptoms chronic schizophrenia
85. A single-blind study of clocapramine and sulpiride in hospitalised chronic schizophrenic patients